Wave Life Sciences Ltd.
- Open
- 5.81
- Day high
- 5.98
- Day low
- 5.79
- Prev close
- 5.81
- Volume
- 1.4M
- Mkt cap
- $1.1B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.2
- P/S
- 15.7
- Yield
- —
- Per share
- —
Wave Life Sciences Ltd. (WVE) is a Healthcare company listed on NASDAQ. The stock is down 11% over the past year.
Wave Life Sciences Ltd. (WVE) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 4 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
WVE earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 28, 2026 | $-0.34 | $-0.13 | +61.8% | $38M | +352.6% |
| Jul 30, 2025 | $-0.29 | $-0.31 | -6.9% | $9M | -11.7% |
| May 8, 2025 | $-0.27 | $-0.29 | -7.4% | $9M | -36.4% |
| Mar 4, 2025 | $-0.17 | $0.17 | +200.0% | $84M | +588.3% |
| May 9, 2024 | $-0.18 | $-0.24 | -33.3% | $13M | -45.4% |
| Mar 6, 2024 | $-0.19 | $-0.15 | +21.1% | $29M | +46.3% |
| Nov 9, 2023 | $-0.18 | $0.07 | +138.9% | $49M | +147.8% |
| Aug 3, 2023 | $-0.32 | $-0.20 | +37.5% | $22M | +178.4% |
| May 3, 2023 | $0.06 | $-0.27 | -550.0% | $13M | -60.0% |
| Mar 22, 2023 | $-0.42 | $-0.47 | -11.9% | $1M | -82.5% |
| Nov 10, 2022 | $-0.48 | $-0.42 | +12.5% | $285000 | -96.5% |
| Aug 11, 2022 | $-0.56 | $-0.62 | -10.7% | $375000 | -90.2% |
WVE insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 30, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Buy | 971,091 | $6.50 |
| Mar 30, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Buy | 351,224 | $6.38 |
| Mar 30, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Buy | 4,954,558 | $6.06 |
| Mar 30, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Buy | 2,495,623 | $6.43 |
| Feb 27, 2026 | Francis Chrisofficer: See Remarks | Sell | 15,294 | $15.00 |
| Feb 27, 2026 | Francis Chrisofficer: See Remarks | Sell | 17,900 | $15.09 |
| Feb 27, 2026 | Francis Chrisofficer: See Remarks | Option | 17,900 | $3.87 |
| Feb 27, 2026 | Francis Chrisofficer: See Remarks | Option | 15,294 | $4.75 |
| Feb 11, 2026 | BOLNO PAULdirector, officer: President and CEO | Grant | 1,000,000 | $12.75 |
| Feb 11, 2026 | Moran Kyleofficer: Chief Financial Officer | Sell | 3,588 | $13.45 |
| Feb 11, 2026 | Francis Chrisofficer: See Remarks | Grant | 232,500 | $12.75 |
| Feb 11, 2026 | BOLNO PAULdirector, officer: President and CEO | Sell | 10,480 | $13.45 |
| Feb 11, 2026 | Francis Chrisofficer: See Remarks | Grant | 38,750 | — |
| Feb 11, 2026 | Vargeese Chandraofficer: See Remarks | Grant | 45,625 | — |
| Feb 11, 2026 | Francis Chrisofficer: See Remarks | Sell | 1,883 | $13.45 |
Source: WVE SEC Form 4 filings, latest Mar 30, 2026. For informational purposes only — not investment advice.
See the full WVE insider & 13F page →Wave Life Sciences Ltd. company profile
Overview
Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage genetic medicine company founded in 2012 and based in Singapore. The company specializes in developing novel stereopure oligonucleotides through its proprietary PRISM discovery and drug development platform. Wave went public in November 2015 and has since established itself as a pioneer in the field of RNA-targeted therapeutics, with a particular focus on rare genetic diseases and common conditions like obesity. The company has built strategic partnerships with major pharmaceutical companies including Pfizer, Takeda, and GlaxoSmithKline to advance its innovative therapeutic approaches.
Business
Wave Life Sciences operates in the biotechnology sector, specifically focusing on genetic medicine through RNA-targeted therapeutics. The company's core technology revolves around designing and producing oligonucleotides - short DNA or RNA molecules that can bind to specific RNA sequences to modulate gene expression. The company's primary platform, called PRISM, enables the discovery and development of stereopure oligonucleotides. These molecules work by targeting ribonucleic acid (RNA) to either reduce the expression of disease-promoting proteins, restore the production of functional proteins, or modulate protein expression in other ways. This approach allows Wave to address genetic diseases at their root cause by correcting or compensating for faulty genetic instructions. Wave's pipeline consists of several key therapeutic areas: 1. **Central Nervous System (CNS) Disorders** (approximately 60-70% of pipeline focus): This includes programs for Huntington's disease (WVE-003), amyotrophic lateral sclerosis and frontotemporal dementia (WVE-004), and spinocerebellar ataxia. These conditions are caused by genetic mutations that lead to the production of toxic proteins or the loss of essential proteins in the brain. 2. **Neuromuscular Diseases** (approximately 15-20% of pipeline focus): The company's lead program here is WVE-N531 for Duchenne muscular dystrophy (DMD), a genetic disorder that causes progressive muscle weakness due to the absence of dystrophin protein. 3. **Hepatic (Liver) Indications** (approximately 10-15% of pipeline focus): Wave is developing treatments for Alpha-1 antitrypsin deficiency (AATD) using its novel RNA editing approach, which aims to correct genetic mutations directly. 4. **Metabolic Diseases** (emerging focus): The company has recently entered the obesity space with WVE-007, targeting the INHBE gene to promote weight loss without muscle mass reduction. 5. **Retinal Diseases** (preclinical): Programs for Usher syndrome type 2A and retinitis pigmentosa are in early development.
Revenue model
Wave Life Sciences generates revenue through multiple business models typical of clinical-stage biotechnology companies. The primary revenue sources include collaboration agreements with pharmaceutical partners, where Wave receives upfront payments, milestone payments, and research funding. For example, the company has a significant partnership with GlaxoSmithKline that provided a $170 million upfront payment and could potentially deliver up to $2.8 billion in milestone payments. The company's paying customers are primarily large pharmaceutical companies who partner with Wave to access its proprietary PRISM platform and drug candidates. These partners pay for research costs, development milestones, and eventually licensing fees or royalties on successful products. Wave's 2024 revenue of $108.3 million came predominantly from these collaboration arrangements. Several factors significantly impact Wave's financial performance and margins: **Positive margin drivers** include successful clinical trial outcomes that trigger milestone payments, new partnership agreements that provide upfront cash, and the advancement of multiple programs simultaneously which diversifies risk and revenue potential. The company's RNA editing platform represents a particularly valuable asset as it addresses previously undruggable genetic targets. **Negative margin pressures** stem from the high costs and risks inherent in drug development. Clinical trials are expensive, with Wave's R&D expenses reaching $159.7 million in 2024. The company faces regulatory risks where programs may fail to meet endpoints or encounter safety issues. Additionally, Wave operates in a competitive landscape where other companies are developing similar RNA-targeted approaches, and the company must continuously invest in platform improvements to maintain its technological edge. The biotechnology sector is also subject to broader market volatility, changes in regulatory requirements, and shifts in investor sentiment toward clinical-stage companies. Wave's cash burn rate of approximately $150 million annually means the company must carefully manage its capital and potentially seek additional funding or partnerships to sustain operations through clinical development phases.
Competitive moat
Wave Life Sciences possesses a moderate technological moat built around its proprietary PRISM platform and stereopure oligonucleotide chemistry. The company's key competitive advantages include its ability to design molecules with precise stereochemistry, which can improve efficacy and reduce side effects compared to traditional approaches. Wave has also demonstrated unique capabilities in RNA editing, becoming the first company to achieve clinical RNA editing in humans with its AATD program. The company's intellectual property portfolio and specialized expertise in oligonucleotide design create barriers to entry, particularly in the complex field of allele-selective targeting for genetic diseases. Wave's partnerships with major pharmaceutical companies also provide validation of its technology and create switching costs for these partners who have invested significantly in the collaboration. However, the moat faces several challenges and potential disruptions. The broader oligonucleotide therapeutics space is highly competitive, with well-funded companies like Ionis Pharmaceuticals, Alnylam Pharmaceuticals, and others developing similar RNA-targeted approaches. Large pharmaceutical companies are also building internal capabilities in this area, potentially reducing their reliance on external partnerships. The regulatory pathway for genetic medicines remains complex and evolving, creating uncertainty around approval timelines and requirements. Additionally, Wave's approach, while innovative, is still largely unproven at commercial scale, with most programs in early to mid-stage clinical development. The company's moat will ultimately depend on its ability to demonstrate superior clinical outcomes and successfully navigate the regulatory process ahead of competitors. Manufacturing and delivery challenges also pose risks, as oligonucleotide therapies require specialized production capabilities and often face tissue-targeting limitations. Wave's success in strengthening its moat will depend on continued innovation, successful clinical execution, and the ability to establish first-mover advantages in specific therapeutic areas.
Risks & safety
Wave Life Sciences presents a **moderate to high-risk** investment profile typical of clinical-stage biotechnology companies, with significant cash reserves but substantial ongoing losses. **Cash and Solvency Position:** - Strong cash position of $302.1 million as of Q4 2024, sufficient to fund operations into 2027 - Current ratio of 2.89, indicating good short-term liquidity - Annual cash burn of approximately $150 million, requiring careful capital management - Debt-to-equity ratio of 0.12, representing minimal debt burden **Valuation Metrics:** - Price-to-book ratio of 8.16, reflecting premium valuation typical of biotech companies - Negative price-to-earnings ratio due to operating losses, common for clinical-stage companies - Enterprise value reflects significant cash holdings and collaboration milestone potential **Other Key Considerations:** - Clinical trial risks across multiple programs could impact timeline and funding needs - Regulatory approval uncertainty for novel RNA editing approaches - Partnership dependency for revenue generation and validation - Competitive pressures in rapidly evolving oligonucleotide therapeutics space
Recent development
Wave Life Sciences has undergone significant strategic evolution over the past few years, transitioning from a pure oligonucleotide antisense company to a leader in RNA editing therapeutics. The most notable development has been the company's pioneering work in clinical RNA editing, with WVE-006 for Alpha-1 antitrypsin deficiency becoming the first program to demonstrate RNA editing in humans, achieving 6.9 micromolar circulating corrected protein levels. The company has strategically expanded into the obesity market with WVE-007, targeting the INHBE gene to promote weight loss without muscle mass reduction. This program represents a significant pivot toward addressing common diseases with large market potential, complementing Wave's rare disease focus. Preclinical data suggests the approach could offer advantages over existing GLP-1 therapies by preserving muscle mass during weight loss. Wave has also strengthened its partnership strategy, most notably through the expanded collaboration with GlaxoSmithKline that provided $170 million upfront and potential milestone payments up to $2.8 billion. This partnership validates Wave's PRISM platform and provides substantial non-dilutive funding for continued development. In the Huntington's disease program, Wave achieved breakthrough results with WVE-003, demonstrating up to 46% reduction in mutant huntingtin protein and establishing a correlation between protein reduction and slowing of brain atrophy. The FDA has indicated support for a potential accelerated approval pathway using caudate atrophy as a biomarker. The company has also made significant progress in Duchenne muscular dystrophy, with WVE-N531 showing consistent dystrophin protein expression of 9% in clinical trials. Wave is preparing for regulatory feedback on this program and potential accelerated approval pathways. Looking ahead, Wave is expanding its discovery pipeline to include additional RNA editing targets for both hepatic and extra-hepatic applications, with plans to initiate clinical development of new programs in 2026.
WVE company profile · for informational purposes only — not investment advice.
Track WVE with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free